Literature DB >> 22896619

A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin.

Anette Schneemann1, Jeffrey A Speir, Gene S Tan, Reza Khayat, Damian C Ekiert, Yumiko Matsuoka, Ian A Wilson.   

Abstract

The discovery of broadly neutralizing antibodies that recognize highly conserved epitopes in the membrane-proximal region of influenza virus hemagglutinin (HA) has revitalized efforts to develop a universal influenza virus vaccine. This effort will likely require novel immunogens that contain these epitopes but lack the variable and immunodominant epitopes located in the globular head of HA. As a first step toward developing such an immunogen, we investigated whether the 20-residue A-helix of the HA2 chain that forms the major component of the epitope of broadly neutralizing antibodies CR6261, F10, and others is sufficient by itself to elicit antibodies with similarly broad antiviral activity. Here, we report the multivalent display of the A-helix on icosahedral virus-like particles (VLPs) derived from the capsid of Flock House virus. Mice immunized with VLPs displaying 180 copies/particle of the A-helix produced antibodies that recognized trimeric HA and the elicited antibodies had binding characteristics similar to those of CR6261 and F10: they recognized multiple HA subtypes from group 1 but not from group 2. However, the anti-A-helix antibodies did not neutralize influenza virus. These results indicate that further engineering of the transplanted peptide is required and that display of additional regions of the epitope may be necessary to achieve protection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22896619      PMCID: PMC3486276          DOI: 10.1128/JVI.01694-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  EMAN: semiautomated software for high-resolution single-particle reconstructions.

Authors:  S J Ludtke; P R Baldwin; W Chiu
Journal:  J Struct Biol       Date:  1999-12-01       Impact factor: 2.867

2.  Accurate determination of local defocus and specimen tilt in electron microscopy.

Authors:  Joseph A Mindell; Nikolaus Grigorieff
Journal:  J Struct Biol       Date:  2003-06       Impact factor: 2.867

Review 3.  The coming of age of virus-like particle vaccines.

Authors:  Gary T Jennings; Martin F Bachmann
Journal:  Biol Chem       Date:  2008-05       Impact factor: 3.915

Review 4.  The structure and function of nodavirus particles: a paradigm for understanding chemical biology.

Authors:  A Schneemann; V Reddy; J E Johnson
Journal:  Adv Virus Res       Date:  1998       Impact factor: 9.937

5.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

6.  Induction of a protective immune response against viral nervous necrosis in the European sea bass Dicentrarchus labrax by using betanodavirus virus-like particles.

Authors:  R Thiéry; J Cozien; J Cabon; F Lamour; M Baud; A Schneemann
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.

Authors:  Bruno E Correia; Yih-En Andrew Ban; Margaret A Holmes; Hengyu Xu; Katharine Ellingson; Zane Kraft; Chris Carrico; Erica Boni; D Noah Sather; Camille Zenobia; Katherine Y Burke; Tyler Bradley-Hewitt; Jessica F Bruhn-Johannsen; Oleksandr Kalyuzhniy; David Baker; Roland K Strong; Leonidas Stamatatos; William R Schief
Journal:  Structure       Date:  2010-09-08       Impact factor: 5.006

8.  A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins.

Authors:  Davide Corti; Jarrod Voss; Steven J Gamblin; Giosiana Codoni; Annalisa Macagno; David Jarrossay; Sebastien G Vachieri; Debora Pinna; Andrea Minola; Fabrizia Vanzetta; Chiara Silacci; Blanca M Fernandez-Rodriguez; Gloria Agatic; Siro Bianchi; Isabella Giacchetto-Sasselli; Lesley Calder; Federica Sallusto; Patrick Collins; Lesley F Haire; Nigel Temperton; Johannes P M Langedijk; John J Skehel; Antonio Lanzavecchia
Journal:  Science       Date:  2011-07-28       Impact factor: 47.728

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  A viral nanoparticle with dual function as an anthrax antitoxin and vaccine.

Authors:  Darly J Manayani; Diane Thomas; Kelly A Dryden; Vijay Reddy; Marc E Siladi; John M Marlett; G Jonah A Rainey; Michael E Pique; Heather M Scobie; Mark Yeager; John A T Young; Marianne Manchester; Anette Schneemann
Journal:  PLoS Pathog       Date:  2007-10-05       Impact factor: 6.823

View more
  30 in total

1.  Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.

Authors:  Frederick W Holtsberg; Sergey Shulenin; Hong Vu; Katie A Howell; Sonal J Patel; Bronwyn Gunn; Marcus Karim; Jonathan R Lai; Julia C Frei; Elisabeth K Nyakatura; Larry Zeitlin; Robin Douglas; Marnie L Fusco; Jeffrey W Froude; Erica Ollmann Saphire; Andrew S Herbert; Ariel S Wirchnianski; Calli M Lear-Rooney; Galit Alter; John M Dye; Pamela J Glass; Kelly L Warfield; M Javad Aman
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

2.  Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection.

Authors:  Vamsee V A Mallajosyula; Michael Citron; Francesca Ferrara; Xianghan Lu; Cheryl Callahan; Gwendolyn J Heidecker; Siddhartha P Sarma; Jessica A Flynn; Nigel J Temperton; Xiaoping Liang; Raghavan Varadarajan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-09       Impact factor: 11.205

Review 3.  Virus-like particles as antigenic nanomaterials for inducing protective immune responses in the lung.

Authors:  Agnieszka Rynda-Apple; Dustin P Patterson; Trevor Douglas
Journal:  Nanomedicine (Lond)       Date:  2014       Impact factor: 5.307

Review 4.  Virus-Based Nanoparticles as Versatile Nanomachines.

Authors:  Kristopher J Koudelka; Andrzej S Pitek; Marianne Manchester; Nicole F Steinmetz
Journal:  Annu Rev Virol       Date:  2015-09-25       Impact factor: 10.431

Review 5.  Vaccine design: emerging concepts and renewed optimism.

Authors:  Sebastian K Grimm; Margaret E Ackerman
Journal:  Curr Opin Biotechnol       Date:  2013-03-07       Impact factor: 9.740

Review 6.  The prospects and challenges of universal vaccines for influenza.

Authors:  Kanta Subbarao; Yumiko Matsuoka
Journal:  Trends Microbiol       Date:  2013-05-17       Impact factor: 17.079

7.  Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.

Authors:  Kosuke Okuya; Reiko Yoshida; Rashid Manzoor; Shinji Saito; Tadaki Suzuki; Michihito Sasaki; Takeshi Saito; Yurie Kida; Akina Mori-Kajihara; Tatsunari Kondoh; Masahiro Sato; Masahiro Kajihara; Hiroko Miyamoto; Osamu Ichii; Hideaki Higashi; Ayato Takada
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

8.  Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.

Authors:  Greg A Kirchenbaum; Donald M Carter; Ted M Ross
Journal:  J Virol       Date:  2015-11-11       Impact factor: 5.103

Review 9.  Influenza virus hemagglutinin stalk-based antibodies and vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Curr Opin Virol       Date:  2013-08-24       Impact factor: 7.090

Review 10.  Novel universal influenza virus vaccine approaches.

Authors:  Florian Krammer
Journal:  Curr Opin Virol       Date:  2016-02-27       Impact factor: 7.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.